Two Cannabinoids, Two Distinct Profiles

Cannabis contains more than a hundred cannabinoids, but two of them are particularly well known: THC (tetrahydrocannabinol) and CBD (cannabidiol). Although they come from the same plant, their effects and legal status differ significantly.

THC: A Psychoactive Cannabinoid

THC is the molecule responsible for the psychoactive effects of cannabis. By binding to receptors of the endocannabinoid system, particularly in the brain, it can influence perception, attention, or mood.

This is why THC is strictly regulated in Switzerland: above 1% THC, a product is considered a controlled substance and cannot be sold freely.

CBD: A Non-Psychoactive Cannabinoid

CBD, unlike THC, does not produce psychoactive effects. It also interacts with the endocannabinoid system, but without altering perception or behaviour.

For this reason, CBD is legal in Switzerland as long as it complies with national regulations, particularly with a THC level below 1%. Consumers appreciate CBD for its natural profile, its non-intoxicating character, and its ease of use in everyday routines.

CBD and THC: Two Complementary Molecules

Although often contrasted, THC and CBD can balance each other in certain cannabis varieties. CBD is known to moderate the intensity of THC in some contexts, which is why many users prefer cannabinoid profiles where the two are harmonised.

In the Swiss legal market, products focus primarily on CBD, with a minimal and compliant THC content.

Understanding the Difference to Make Informed Choices

Knowing the distinction between CBD and THC helps explain the origins of different effects and allows consumers to identify products suited to their preferences. In Switzerland, the legal framework is clear: CBD is permitted as long as regulatory limits are respected, while THC remains strictly regulated.

For a safe, informed and fully compliant experience, it is essential to understand the differences between these two key cannabinoids of the cannabis plant.